Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Feb;51(2):119–125. doi: 10.1136/thx.51.2.119

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.

P L Shah 1, S F Scott 1, R A Knight 1, C Marriott 1, C Ranasinha 1, M E Hodson 1
PMCID: PMC473012  PMID: 8711640

Abstract

BACKGROUND: Viscoelastic secretions in cystic fibrosis cause impaired mucus clearance and persistence of bacteria within the lung. The abnormal rheology is partly due to the presence of high molecular weight deoxyribonucleic acid (DNA). Recombinant human DNase I (rhDNase) has been shown to depolymerise DNA and thereby reduce the in vitro viscoelasticity of sputum in patients with cystic fibrosis. A phase II double blind placebo controlled study showed that rhDNase improved pulmonary function in patients with cystic fibrosis. The object of the present study was to evaluate the in vivo effects of rhDNase on sputum rheology and to determine whether these were correlated with changes in pulmonary function. METHODS: Patients were randomised to receive either placebo or rhDNase 2.5 mg twice daily for 10 days. Sputum samples were collected in sterile containers during screening and during treatment with the study drug. Pulmonary function and rheological analysis were the primary outcomes evaluated. Other parameters assessed were quantitative sputum bacteriology, sputum DNA concentration, and change in molecular mass of DNA polymers. RESULTS: The viscoelasticity of the sputum in untreated patients with cystic fibrosis was high and treatment with rhDNase reduced all the rheological parameters measured: dynamic storage modulus (a measure of elasticity), dynamic loss modulus (a measure of viscosity), and log complex modulus (a measure of mucus rigidity). The calculated cough clearance index was also improved following treatment with rhDNase. These rheological parameters showed a correlation with forced expiratory volume in one second (FEV1) which was improved by a mean (SE) of 13.3 (5.6)% on day 10 of treatment with rhDNase compared with a change of 0.2 (3.1)% in the placebo group. There was no change in bacterial colony counts or sputum DNA concentrations following treatment with rhDNase, but a small decrease in high molecular weight DNA was observed. CONCLUSIONS: Patients with cystic fibrosis treated with rhDNase show an improvement in rheological properties and pulmonary function, one of the mechanisms being a reduction in the proportion of high molecular weight DNA.

Full text

PDF
119

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aitken M. L., Burke W., McDonald G., Shak S., Montgomery A. B., Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992 Apr 8;267(14):1947–1951. [PubMed] [Google Scholar]
  2. CHERNICK W. S., BARBERO G. J. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics. 1959 Nov;24:739–745. [PubMed] [Google Scholar]
  3. Dulfano M. J., Adler K. B. Physical properties of sputum. VII. Rheologic properties and mucociliary transport. Am Rev Respir Dis. 1975 Sep;112(3):341–347. doi: 10.1164/arrd.1975.112.3.341. [DOI] [PubMed] [Google Scholar]
  4. FitzSimmons S. C. The changing epidemiology of cystic fibrosis. J Pediatr. 1993 Jan;122(1):1–9. doi: 10.1016/s0022-3476(05)83478-x. [DOI] [PubMed] [Google Scholar]
  5. Fuchs H. J., Borowitz D. S., Christiansen D. H., Morris E. M., Nash M. L., Ramsey B. W., Rosenstein B. J., Smith A. L., Wohl M. E. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. doi: 10.1056/NEJM199409083311003. [DOI] [PubMed] [Google Scholar]
  6. GIBSON L. E., COOKE R. E. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959 Mar;23(3):545–549. [PubMed] [Google Scholar]
  7. Hitchcock S. E., Carisson L., Lindberg U. Depolymerization of F-actin by deoxyribonuclease I. Cell. 1976 Apr;7(4):531–542. doi: 10.1016/0092-8674(76)90203-8. [DOI] [PubMed] [Google Scholar]
  8. Hodson M. E., Warner J. O. Cystic fibrosis: respiratory problems and their treatment. Br Med Bull. 1992 Oct;48(4):931–948. doi: 10.1093/oxfordjournals.bmb.a072586. [DOI] [PubMed] [Google Scholar]
  9. Hubbard R. C., McElvaney N. G., Birrer P., Shak S., Robinson W. W., Jolley C., Wu M., Chernick M. S., Crystal R. G. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19;326(12):812–815. doi: 10.1056/NEJM199203193261207. [DOI] [PubMed] [Google Scholar]
  10. King M., Brock G., Lundell C. Clearance of mucus by simulated cough. J Appl Physiol (1985) 1985 Jun;58(6):1776–1782. doi: 10.1152/jappl.1985.58.6.1776. [DOI] [PubMed] [Google Scholar]
  11. King M., Gilboa A., Meyer F. A., Silberberg A. On the transport of mucus and its rheologic simulants in ciliated systems. Am Rev Respir Dis. 1974 Dec;110(6):740–745. doi: 10.1164/arrd.1974.110.6P1.740. [DOI] [PubMed] [Google Scholar]
  12. King M. The role of mucus viscoelasticity in cough clearance. Biorheology. 1987;24(6):589–597. doi: 10.3233/bir-1987-24611. [DOI] [PubMed] [Google Scholar]
  13. Knudson R. J., Lebowitz M. D., Holberg C. J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983 Jun;127(6):725–734. doi: 10.1164/arrd.1983.127.6.725. [DOI] [PubMed] [Google Scholar]
  14. Lazarides E., Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci U S A. 1974 Dec;71(12):4742–4746. doi: 10.1073/pnas.71.12.4742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lethem M. I., James S. L., Marriott C., Burke J. F. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J. 1990 Jan;3(1):19–23. [PubMed] [Google Scholar]
  16. Lethem M. I., James S. L., Marriott C. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis. 1990 Nov;142(5):1053–1058. doi: 10.1164/ajrccm/142.5.1053. [DOI] [PubMed] [Google Scholar]
  17. Penketh A. R., Wise A., Mearns M. B., Hodson M. E., Batten J. C. Cystic fibrosis in adolescents and adults. Thorax. 1987 Jul;42(7):526–532. doi: 10.1136/thx.42.7.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Puchelle E., Zahm J. M., Polu J. M., Sadoul P. Drug effects on viscoelasticity of mucus. Eur J Respir Dis Suppl. 1980;110:195–208. [PubMed] [Google Scholar]
  19. Ramsey B. W., Astley S. J., Aitken M. L., Burke W., Colin A. A., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Schidlow D. V. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993 Jul;148(1):145–151. doi: 10.1164/ajrccm/148.1.145. [DOI] [PubMed] [Google Scholar]
  20. Ranasinha C., Assoufi B., Shak S., Christiansen D., Fuchs H., Empey D., Geddes D., Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993 Jul 24;342(8865):199–202. doi: 10.1016/0140-6736(93)92297-7. [DOI] [PubMed] [Google Scholar]
  21. Ratjen F., Wönne R., Posselt H. G., Stöver B., Hofmann D., Bender S. W. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr. 1985 Nov;144(4):374–378. doi: 10.1007/BF00441781. [DOI] [PubMed] [Google Scholar]
  22. Shak S., Capon D. J., Hellmiss R., Marsters S. A., Baker C. L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188–9192. doi: 10.1073/pnas.87.23.9188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shih C. K., Litt M., Khan M. A., Wolf D. P. Effect of nondialyzable solids concentration and viscoelasticity on ciliary transport of tracheal mucus. Am Rev Respir Dis. 1977 Jun;115(6):989–995. doi: 10.1164/arrd.1977.115.6.989. [DOI] [PubMed] [Google Scholar]
  24. Stafanger G., Garne S., Howitz P., Morkassel E., Koch C. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. 1988 Feb;1(2):161–167. [PubMed] [Google Scholar]
  25. Stafanger G., Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. Eur Respir J. 1989 Mar;2(3):234–237. [PubMed] [Google Scholar]
  26. Vasconcellos C. A., Allen P. G., Wohl M. E., Drazen J. M., Janmey P. A., Stossel T. P. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science. 1994 Feb 18;263(5149):969–971. doi: 10.1126/science.8310295. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES